August 17, 2017

Mr. Daniel O’Day
Chief Executive Officer
Roche Pharmaceuticals
Konzer-Hauptsitz
Grenzacherstrasse 124
CH-4070 Basel
Switzerland

Dear Mr. O’Day:

We are launching an in-depth investigation to determine why drug companies are dramatically increasing their prices for drugs used to treat Multiple Sclerosis (MS), which is a disease of the central nervous system that often has devastating and disabling effects on patients. We believe no American should be forced to struggle to afford lifesaving medical treatments, especially when drug companies increase prices without warning, cause, or justification.

Genentech, a member of the Roche Group, introduced Ocrevus—a drug used to treat relapsing-remitting and primary progressive MS—in March 2017, with a Wholesale Acquisition Cost (WAC) price of $65,000. The company was praised for setting the price of Ocrevus approximately 20% lower than other brand MS drugs currently on the market, but questions have been raised about whether Ocrevus—which is similar to Roche’s 2006 cancer drug Rituxan—is truly a new, breakthrough product or simply the reformulation of an old drug that may soon face biosimilar competition in the U.S. One researcher described Ocrevus as an “expensive, overdosed version of Rituxan” and characterized Genentech’s commercialization of the drug as “shameless.”

Although the price of Ocrevus has remained stable since its introduction five months ago, experts have raised concerns that some drug companies appear to be increasing their prices and setting new, higher prices in lockstep with competitors—a strategy known as “shadow pricing.”

---

1 MS Society, FDA Approves Ocrevus™ (ocrelizumab) for People with Primary Progressive MS or Relapsing MS—First Disease-Modifying Therapy for Primary Progressive MS (Mar. 29, 2017) (online at www.nationalmssociety.org/About-the-Society/News/FDA-Approves-Ocrevus).


3 Id.
When a company increases its price or introduces a new, more expensive drug into the market, other companies increase their prices to match—or shadow—these higher prices.

For example, a study on MS drug prices published by the *American Academy of Neurology* reported that “the dramatic increases in the costs of the first-generation DMTs [disease-modifying therapies] may have been a response to the introduction of competing treatments with higher prices.”4 The study found:

Why the costs of MS DMTs in the United States have risen so dramatically is uncertain. However, the simplest explanation is that pharmaceutical companies raise prices of new and old MS DMTs in the United States to increase profits and our health care system puts no limits on these increases.5

According to this study, annual sales of MS drugs doubled from $4 billion to nearly $9 billion from 2008 to 2012. At the same time, the cost of the average annual disease-modifying MS therapy was $16,050 per patient in 2004, while the average annual cost of the disease-modifying therapy interferon increased to more than $60,000 in 2015.6

As the study noted: “Classic economic theory asserts that competition should reduce or stabilize costs for the consumer as more products enter the market.”7

Unfortunately, this has not been the case in the MS drug market. The prices of more than a dozen MS therapies have increased sharply in the past decade, nearly in lockstep with new, more expensive entrants into the market.8

The MS market also lacks robust competition from the generic market. Currently, the only generic alternative is for the brand drug Copaxone 20 mg, and it is priced at $66,731.9

---


5 Id.

6 Id.

7 Id.


Shortly before this generic was launched, however, the company that sells Copaxone developed a new 40 mg formulation that could be taken less frequently, and it switched approximately 70% of patients to this new formulation—which faces no generic competition. The generic reportedly captured only 25% to 30% of the 20 mg market by 2015.\textsuperscript{10} 1\textsuperscript{11}

In order to evaluate the underlying causes of the skyrocketing prices for MS drugs, we request you provide by August 31, 2017, the following information and documents from 2010 to the present:

1. A list of your company’s profits and expenses for Ocrevus, including, but not limited to:
   a. profit (including operating and net);
   b. sales;
   c. cost of goods sold;
   d. operating cost;
   e. rebates (including commercial, Medicare Part D, and Medicaid rebates);
   f. discounts;
   g. allowances;
   h. coupons;
   i. patient co-pay;
   j. charge backs;
   k. direct selling expenses;
   l. medical affairs;
   m. marketing;
   n. research and development;
   o. Patient Assistance Programs;
   p. taxes; and
   q. any other expenses or costs;

2. all documents, including internal analyses or memoranda, that have been provided to, or prepared for, your company or your Board of Directors, referring or relating to sales, profits, and pricing strategies for Ocrevus;

3. all documents and communications, including internal analyses or memoranda, relating to the use of clinical data or other information about the drug Rituxan (rituximab) in the development of Ocrevus;


(4) all documents and communications relating to any tax deductions or benefits related to patient assistance programs, eligibility requirements and total number of applicants and recipients for Ocrevus;

(5) all documents and communications concerning any efforts to extend the patent life of Ocrevus, including through the development of new drug strengths or formulations;

(6) all documents and communications concerning your company’s use of limited, restricted, or specialty distribution systems for Ocrevus; and

(7) all agreements, contracts, and communications to or from suppliers, distributors, wholesalers, insurers, pharmacy benefit managers, retail pharmacies, and any other partner in the distribution channel for Ocrevus.

If you have any questions about this request, please contact Francesca McCrary with Ranking Member Cummings’ staff at (202) 225-5051. Thank you for your consideration.

Sincerely,

Elijah E. Cummings
Ranking Member

Peter Welch
Member of Congress

cc: The Honorable Trey Gowdy, Chairman